Regen BioPharma, Inc. (OTCMKTS:RGBP) Short Interest Up 687.1% in September

Regen BioPharma, Inc. (OTCMKTS:RGBP) saw a significant increase in short interest in September. As of September 30th, there was short interest totaling 24,400 shares, an increase of 687.1% from the September 15th total of 3,100 shares. Based on an average trading volume of 1,186,400 shares, the short-interest ratio is currently 0.0 days. Based on an average trading volume of 1,186,400 shares, the short-interest ratio is currently 0.0 days.

Regen BioPharma Price Performance

Regen BioPharma has a 12-month low of $0.01 and a 12-month high of $0.27. The stock has a 50 day moving average of $0.02 and a 200-day moving average of $0.04.

Regen BioPharma Company Profile

Regen BioPharma, Inc focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6.